

Market Announcement

4 June 2026

OncoSil Medical Ltd (ASX: OSL) – Trading Halt

Trading in the securities of OncoSil Medical Ltd ('OSL') will be halted at the request of OSL, pending the release of an announcement by OSL.

Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of:

- the commencement of normal trading on Tuesday, 9 June 2026; or
- the release of the announcement to the market.

OSL's request for a trading halt is attached below for the information of the market.

Issued by

ASX Compliance

4 June 2026

Listings Compliance
ASX Limited
Level 27, 39 Martin Place
Sydney NSW 2000

By email: tradinghaltssydney@asx.com.au

Dear ASX

Request for a trading halt - OncoSil Medical Limited (ASX: OSL)

Pursuant to ASX Listing Rule 17.1, OncoSil Medical Limited ACN 113 824 141 (ASX: OSL) (the **Company**) requests that its securities be placed into an immediate trading halt.

In accordance with ASX Listing Rule 17.1 the Company advises that:

- a) The trading halt is requested pending an announcement by the Company in relation to the material results of the TRIPP-FFX clinical trial and regulatory correspondence received from the U.S. Food and Drug Administration (**Purpose**);
- b) The trading halt is requested to remain in place until the earlier of such time as it makes an announcement to the market regarding the Purpose, or the commencement of trading on Tuesday, 9 June 2026;
- c) The Company expects to make the announcement regarding the Purpose to the market before the commencement of normal trading on Tuesday, 9 June 2026; and
- d) The Company is not aware of any reason why the trading halt should not be granted, or of any other information necessary to inform the market about the trading halt.

This request was authorised by the Board of Directors of OncoSil Medical Limited.

Yours faithfully

Mr. Tim Luscombe & Ms. Nova Taylor
Joint Company Secretaries
OncoSil Medical Limited